Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07019259 · ClinicalTrials.gov registry record · NA

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

A NA study of Cancer and Chemotherapy-induced Peripheral Neuropathy, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
2
Study locations

NCT07019259 is a NA study of Cancer and Chemotherapy-induced Peripheral Neuropathy that is actively recruiting participants, run by Yale University. The registered enrollment target is 20 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07019259, a NA study of Cancer and Chemotherapy-induced Peripheral Neuropathy, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.

Interventions

  • DEVICE Anodyne Therapy System

Study Locations (2)

Connecticut

  • Yale New Haven Health Smilow York Street Hospital - New Haven
  • Yale New Haven Health Park Avenue Medical Center - Trumbull

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-06-30
Est. Completion 2026-09
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT07019259

The ClinicalTrials.gov registry entry for NCT07019259 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Anodyne Therapy System is the first listed.

NCT07019259 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT07019259 about?

NCT07019259 is a clinical study titled "Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors". The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy...

What is the current status of trial NCT07019259?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-06-30. Estimated completion is 2026-09.

What conditions does trial NCT07019259 study?

This clinical trial studies the following conditions: Cancer, Chemotherapy-induced Peripheral Neuropathy, Childhood Cancer.

What interventions are being tested in trial NCT07019259?

The interventions under investigation include: Anodyne Therapy System (DEVICE).

Who is sponsoring clinical trial NCT07019259?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07019259 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.